16th July, 2026

To

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 543318

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1,
G Block, Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
Trading Symbol: CLEAN

Subject: **Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "**LODR Regulations**") and Clean Science and Technology Limited's (the "**Company"**) policy on determination of materiality, we hereby inform the stock exchanges that its wholly owned subsidiary, Clean-Fino Chem Limited (the "**Subsidiary**"), has entered into definitive agreements for a long-term strategic collaboration with Geneus Chem AG, a company incorporated under the laws of Switzerland, having its office at Mattenstrasse 22, 4058 Basel, Switzerland ("**GC**").

The collaboration is in line with the Company's business strategy and is expected to support its specialty chemicals portfolio.

Lodha Capital Markets Ltd acted as the financial advisor and AZB & Partners as the legal advisor to the Company for this strategic collaboration agreement.

The details required under Regulation 30 read with Schedule III of the LODR Regulations are enclosed as **Annexure A, Annexure B and Annexure C** below.

The intimation is also being uploaded on the website of the Company at www.cleanscience.co.in

You are requested to take above information on record.

Thanking You.

For Clean Science and Technology Limited

Ruchita Vij
Digitally signed by Ruchita Vij
Date: 2026.07.16 18:49:44 +05'30'

Ruchita Vij
Company Secretary & Compliance Officer

Annexure A

AGREEMENT TO ACQUIRE

Details required under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Target entity is Geneus Chem AG a company incorporated under the laws of Switzerland, having its office at Mattenstrasse 22, 4058 Basel, Switzerland ("**GC**"). GC is a start-up company which was incorporated in 2022. Based on the information available with the Company, GC is not operating at a significant scale including in terms of revenues.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The Subsidiary has entered into a long-term manufacturing/ supply agreement with GC in terms of which the Subsidiary has agreed to manufacture advanced grades of HALS Products. In lieu of above collaboration, GC has agreed to issue warrants to the Subsidiary which are exercisable by the Subsidiary within the exercise period. The agreement to acquire does not constitute a related party transaction/ None of the promoters/ promoter group/ group companies have any interest in GC.
3.	Industry to which the entity being acquired belongs	GC is engaged in the business of research, development, sales, manufacturing, trading, export and import of chemical products as well as consulting and analytical services in this, in particular, with advanced grades of HALS Products.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Subsidiary has entered into long term collaboration with GC for supply of advance grade of HALS. The collaboration is in line with the Company's business strategy and is expected to support its specialty chemicals portfolio.

5.	Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approvals are required for the proposed acquisition of GC by the Subsidiary.
6.	Indicative time period for completion of the acquisition.	The share warrants proposed to be issued to the Subsidiary by GC in terms of the Subscription Agreement are exercisable within four years from the date of issuance of such share warrants by GC.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	At the time of exercise of the share warrants by the Subsidiary, the Subsidiary will be required to pay a nominal price per company share to GC.
8.	Cost of acquisition and/or the price at which the shares are acquired	The share warrants proposed to be issued to the Subsidiary by GC in terms of the subscription agreement are exercisable within four years from the date of issuance of such share warrants by GC. No consideration is payable by the Subsidiary for subscription to share warrants.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Upon exercise of the share warrants, the Subsidiary will acquire 25% of the share capital of GC on a fully diluted basis.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	GC is Swiss company which was incorporated in 2022. GC is engaged in the business of research, development, sales, manufacturing, trading, export and import of chemical products as well as consulting and analytical services in this, in particular, with advanced grades of HALS Products. Based on the information available with the Company, GC is not operating at a significant scale including in terms of revenues.

ANNEXURE B

DISCLOSURES UNDER PARA 5A OF PARA A OF PART A OF SCHEDULE III

Details required under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015

Sr. No.	Particulars	Details
1.	If the listed entity is a party to the agreement, (i) details of the counterparties (including name and relationship with the listed entity);	Not applicable. The Company is not party to the definitive agreements. The definitive agreements have been executed with the Subsidiary.
2.	If listed entity is not a party to the agreement, (i) name of the party entering into such an agreement and the relationship with the listed entity; (ii) details of the counterparties to the agreement (including name and relationship with the listed entity); (iii) date of entering into the agreement	(a) Clean-Fino Chem Limited, wholly owned subsidiary of the Company is party to the definitive agreements. (b) Other parties to the definitive agreements are GC and the co-founders of GC. GC and the co-founders are not related to the Company. (c) The definitive agreements have been executed on July 16, 2026.
3.	Purpose of entering into the agreement.	The definitive agreements have been executed in relation to a long term strategic collaboration with GC.
4.	Shareholding, if any, in the entity with whom the agreement is executed.	The Company does not hold any shares in GC.
5.	Significant terms of the agreement (in brief)	The definitive agreements are on customary commercial terms for a long-term supply collaboration and include, inter alia, provisions relating to minimum offtake commitments, pricing mechanism, product specifications, non-compete obligations, supply obligations, confidentiality, intellectual property, representations and warranties, indemnities, term and termination, and dispute resolution thereof.

6.	Extent and the nature of impact on management or control of the listed entity.	Not applicable
7.	Details and quantification of the restriction or liability imposed upon the listed entity.	Please refer to para (5) above.
8.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship.	Other than the Subsidiary, the other parties to the definitive agreements are not related to the Company.
9.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	Not applicable
10.	In case of issuance of shares to the parties, details of issue price, class of shares issued.	The Company is not required to issue any shares to the parties.
11.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not applicable
12.	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s): (i) name of parties to the agreement; (ii) nature of the agreement; (iii) date of execution of the agreement; (iv) details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier);	Not applicable

ANNEXURE C

FOR ARRANGEMENTS FOR STRATEGIC, TECHNICAL, MANUFACTURING, OR MARKETING TIE UP

Sr. No.	Particulars	Details
1.	Agreement / joint venture (JV) with companies: (i) name of the entity(ies) with whom agreement/ JV is signed; (ii) area of agreement/JV; (iii) domestic/international; (iv) share exchange ratio / JV ratio; (v) scope of business operation of agreement / JV; (vi) details of consideration paid / received in agreement / JV; (vii) significant terms and conditions of agreement / JV in brief; (viii) whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	(i) Manufacturing agreement has been executed by the Subsidiary with GC and its co-founders. (ii) In terms of the manufacturing agreement, the subsidiary has agreed to manufacture advanced grades of HALS Products on a worldwide 'exclusive basis' (iii) The manufacturing operations will be undertaken domestically. The advanced grades of HALS Products will be sold domestically as well as internationally. (iv) Not applicable (v) Please refer to (ii) above. (vi) The consideration to be received for manufacturing will be based on a pricing formula to be agreed between the parties. (vii) In lieu of above collaboration, GC has agreed to issue warrants to the Subsidiary which are exercisable by the Subsidiary within the exercise period. (viii) Not applicable (ix) Not available in the public domain. (x) The collaboration is in line with the Company's business strategy and is expected to support (xi) its specialty chemicals portfolio.

	(ix) size of the entity(ies); (x) rationale and benefit expected.	
2.	In the event that any such arrangement is called off for any reason, the same shall be disclosed along with the reasons for calling off the proposal.	Not applicable